BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 23317929)

  • 1. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
    Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
    J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series.
    Seinen ML; de Boer NK; Smid K; van Asseldonk DP; Bouma G; van Bodegraven AA; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1085-90. PubMed ID: 22132961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
    Wall GC; Muktar H; Effken C; Mahajan PB
    Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.
    Gerich ME; Quiros JA; Marcin JP; Tennyson L; Henthorn M; Prindiville TP
    J Crohns Colitis; 2010 Nov; 4(5):546-52. PubMed ID: 21122558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited intra-individual variability in hypoxanthine-Guanine phosphoribosyl transferase, thiopurine S-methyl transferase, and xanthine oxidase activity in inflammatory bowel disease patients during 6-thioguanine therapy.
    van Asseldonk DP; de Boer NK; Smid K; Mulder CJ; van Bodegraven AA; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):284-90. PubMed ID: 20544508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.
    Haglund S; Taipalensuu J; Peterson C; Almer S
    Br J Clin Pharmacol; 2008 Jan; 65(1):69-77. PubMed ID: 17662091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio.
    Gardiner SJ; Gearry RB; Burt MJ; Chalmers-Watson T; Chapman BA; Ross AG; Stedman CA; Huelsen A; Barclay ML
    J Gastroenterol Hepatol; 2011 Jan; 26(1):49-54. PubMed ID: 21175793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine.
    Jharap B; de Boer N; Vos R; Smid K; Zwiers A; Peters G; Mulder C; Wilhelm A; van Bodegraven A
    Br J Pharmacol; 2011 Jun; 163(4):722-31. PubMed ID: 21323897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
    Smith MA; Blaker P; Marinaki AM; Anderson SH; Irving PM; Sanderson JD
    J Crohns Colitis; 2012 Oct; 6(9):905-12. PubMed ID: 22386736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
    Brackett J; Schafer ES; Leung DH; Bernhardt MB
    Pediatr Blood Cancer; 2014 Jun; 61(6):1114-7. PubMed ID: 24376133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat as a novel option to optimize thiopurines' metabolism in patients with inadequate metabolite levels.
    Doré M; Frenette AJ; Mansour AM; Troyanov Y; Bégin J
    Ann Pharmacother; 2014 May; 48(5):648-51. PubMed ID: 24523395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
    Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
    Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
    Curkovic I; Rentsch KM; Frei P; Fried M; Rogler G; Kullak-Ublick GA; Jetter A
    Eur J Clin Pharmacol; 2013 Aug; 69(8):1521-31. PubMed ID: 23588559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease.
    Vikingsson S; Andersson D; Almer S; Peterson C; Hindorf U
    J Crohns Colitis; 2014 Dec; 8(12):1702-9. PubMed ID: 25239576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.